New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1669-1679

  Zuccotti, Gianna ^a   Strasfeld, Lynne ^b   Weinstock, David M ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Bone Marrow Transplant Service   (United States)

Author keywords

Infection; Prophylaxis; Stem cell transplant

Indexed keywords

ACICLOVIR; AMANTADINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CIPROFLOXACIN; CYCLOSPORIN; DAPTOMYCIN; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GATIFLOXACIN; GEMIFLOXACIN; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; METHOTREXATE; MOXIFLOXACIN; MYCOPHENOLIC ACID; RIMANTADINE; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VANCOMYCIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW TOXICITY; CANCER; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG PENETRATION; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; INFECTION CONTROL; INFECTION RISK; INJECTION SITE REACTION; MYALGIA; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; RECIPIENT; RESPIRATORY TRACT INFECTION; REVIEW; THROMBOCYTOPENIC PURPURA; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; DRUGS, INVESTIGATIONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS;

EID: 23844502097     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1669     Document Type: Review

References (85)

1. BOECKH M, NICHOLS WG, MARR KA: Long-term care after haematopoietic-cell transplantation in adults. N. Engl. J. Med. (2002) 347:1625-1626.
2. CENTERS FOR DISEASE CONTROL AND PREVENTION; INFECTIOUS DISEASES SOCIETY OF AMERICA; AMERICAN SOCIETY OF BLOOD AND MARROW TRANSPLANTATION: Guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant (2000) 6(6):659-713.
3. TRIFILIO S, VERMA A, MEHTA J: Antimicrobial prophylaxis in haematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant (2004) 33:735-739.
4. FRASER GA, WALKER II: Cytomegalovirus prophylaxis and treatment after haematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol. Blood Marrow Transplant (2004) 10:287-297.
5. VILLABLANCA JG, STEINER M, KERSEY J et al.: The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant (1990) 5:387-393.
6. AVERY R, KALAYCIO M, POHLMAN B et al.: Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant (2005) 35:497-499.
7. ARNS DA CUNHA C, WEISDORF D, SHU XO et al.: Early Gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant (1998) 21:173-180.
8. ENGELS FA, ELLIS CA, SUPRAN SE et al.: Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin. Infect. Dis. (1999) 28:256-266.
9. CRUCIANI M, RAMPAZZO R, MALENA M et al.: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin. Infect. Dis. (1996) 23:795-805.
10. BROUN ER, WHEAT JL, KNEEBONE PH et al.: Randomized trial of the addition of Gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob. Agents Chemother. (1994) 38:576-579.
11. CLASSEN DC, BURKE JP, FORD CD et al.: Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am. J. Med. (1990) 89:441-446.
12. FELD R: Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin. Infect. Dis. (1999) 29:503-507.
13. KERSUN LS, PROPERT KJ, LAUTENBACH E et al.: Early bacteremia in pediatric haematopoietic stem cell transplant patients on oral antibiotic prophylaxis. Pediatr. Blood Cancer (2005) 45(2):162-169.
14. CRUCIANI M, MALENA M, BOSCO O et al.: Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J. Clin. Oncol. (2003) 21:4127-4137.
15. ENGELS EA, LAU J, BARZA M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J. Clin. Oncol. (1998) 16:1179-1187.
16. KERN WV, KLOSE K, JELLEN-RITTER AS et al.: Fluoroquinolone resistance of Escherichia coli at a cancer centre: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukaemia. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:111-118.
17. KERN WV, ANDRIOF E, OETHINGER M et al.: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer centre. Antimicrob. Agents Chemother. (1994) 38:681-687.
18. DETTENKOFER M, EBNER W, BERTZ H et al.: Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant (2003) 31:795-801.
19. CARRATALA J, FERNANDEZ-SEVILLA A, TUBAU F et al.: Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. (1995) 20:557-560.
20. HARTMAN CS, TACK KJ, AZIE E et al.: Linezolid versus vancomycin: efficacy in febrile neutropenic oncology patients. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004) L992.
21. WUNDERINK RG, RELLO J, CAMMARATA SK et al.: Linezolid versus vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124:1789-1797.
22. DIBO I, PILLAI SK, GOLD HS et al.: Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J. Clin. Microbiol. (2004) 42:1843-1845.
23. BURLESON BS, RITCHIE DJ, MICEK ST et al.: Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy (2004) 24:1225-1231.
24. DVORCHIK BH, BRAZIER D, DEBRUIN MF et al.: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. (2003) 47:1318-1323.
25. LAPLANTE KL, RYBAK MJ: Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin. Pharmacother. (2004) 5:2321-2331.
26. MONTECALVO MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. (2003) 51(Suppl. 3):iii31-iii5.
27. WONG MT, KAUFFMAN CA, STANDIFORD HC et al.: Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin. Infect. Dis. (2001) 33:1476-1482.
28. GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. (1992) 326:845-851.
29. SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171:1545-1552.
30. MARR KA, SEIDEL K, SLAVIN MA et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood (2000) 96:2055-2061.
31. PFALLER MA, DIEKEMA DJ, JONES RN et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. (2001) 39:3254-3259.
32. PFALLER MA, DIEKEMA DJ, MESSER SA et al.: Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol. (2003) 41:1440-1446.
33. BARRETT JP, VARDULAKI KA, CONLON C et al.: A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. (2003) 25:1295-320.
34. ALEXANDER BD, WINGARD JR: Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. (2005) 40(Suppl. 6):S414-S421.
35. WINSTON DJ, MAZIARZ RT, CHANDRASEKAR PH et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic haematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med. (2003) 138:705-713.
36. MARR KA, CRIPPA F, LEISENRING W et al.: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2004) 103:1527-1533.
37. ESPINEL-INGROFF A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36:198-202.
38. PAPHITOU NI, OSTROSKY-ZEICHNER L, PAETZNICK VL et al.: In vitro antifungal susceptibilities of Trichosporon species, Antimicrob. Agents Chemother. (2002) 46:1144-1146.
39. KAUFFMAN CA, ZARINS LT: In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis. (1998) 31:297-300.
40. PFALLER MA, MESSER SA, BOYKEN L et al.: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. (2004) 48:201-205.
41. MARTY FM, COSIMI LA, BADEN LR: Breakthrough zygomycosis after voriconazole treatment in recipients of haematopoietic stem-cell transplants. N. Engl. J. Med. (2004) 350:950-952.
42. SIWEK GT, DODGSON KJ, DE MAGALHAES-SILVERMAN M et al.: Invasive zygomycosis in haematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. (2004) 39:584-587.
43. IMHOF A, BALAJEE SA, FREDRICKS DN et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. (2004) 39:743-746.
44. CUDILLO L, GIRMENIA C, SANTILLI S et al.: Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin. Infect. Dis. (2005) 40:1212-1213.
45. HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347:408-415.
46. WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346:225-234.
47. DIEKEMA DJ, MESSER SA, HOLLIS RJ et al.: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. (2003) 41:3623-3626.
48. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326-2332.
49. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46:3001-3012.
50. POWLES MA, LIBERATOR P, ANDERSON J et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. (1998) 42:1985-1989.
51. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
52. VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing haematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39:1407-1416.
53. DE WET N, LLANOS-CUENTAS A, SULEIMAN J et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39:842-849.
54. TRENSCHEL R, DITSCHKOWSKI M, ELMAAGACLI AH et al.: Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant (2005) 35:583-586.
55. MARR KA, BOECKH M, CARTER RA et al.: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39:797-802.
56. ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer (2003) 97:1025-1032.
57. KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer (2003) 98:292-299.
58. BOECKH M, NICHOLS WG, PAPANICOLAOU G et al.: Cytomegalovirus in haematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant (2003) 9:543-558.
59. BOECKH M, FRIES B, NICHOLS WG: Recent advances in the prevention of CMV infection and disease after haematopoietic stem cell transplantation. Pediatr. Transplant (2004) 8(Suppl. 5):19-27.
60. KIM DH, KIM JG, LEE NY et al.: Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. Bone Marrow Transplant (2004) 34:21-27.
61. BOECKH M, GOOLEY TA, MYERSON D et al.: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood (1996) 88:4063-4071.
62. WINSTON DJ, HO WG, BARTONI K et al.: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann. Intern. Med. (1993) 118:179-184.
63. GOODRICH JM, BOWDEN RA, FISHER L et al.: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. (1993) 118:173-178.
64. WARKENTIN DI, EPSTEIN JB, CAMPBELL LM et al.: Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann. Pharmacother. (2002) 36:1525-1531.
65. WEINSTOCK DM, BOECKH M, BOULAD F et al.: Postexposure prophylaxis against Varicella zoster virus infection among recipients of haematopoietic stem cell transplant: unresolved issues. Infect. Control Hosp. Epidemiol. (2004) 25:603-608.
66. WINSTON DJ, YEAGER AM, CHANDRASEKAR PH et al.: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin. Infect. Dis. (2003) 36:749-758.
67. AKALIN E, BROMBERG JS, SEHGAL V et al.: Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am. J. Transplant (2004) 4:148-149.
68. BABEL N, GABDRAKHMANOVA L, JUERGENSEN JS et al.: Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single centre experience. Transplantation (2004) 78:283-285.
69. CIANCIO G, BURKE GW, MATTIAZZI A et al.: Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin. Transplant. (2004) 18:402-406.
70. KALPOE JS, SCHIPPERS EF, ELING Y et al.: Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir. Ther. (2005) 10:119-123.
71. REUSSER P, EINSELE H, HEBART H et al.: Systemic exposure to ganciclovir (GVD) during preemptive therapy of cytomegalovirus (CMV) infection with oral valganciclovir (VALGCV) is comparable to that with intravenous (IV) GCV in allogeneic stem cell transplant (alloSCT) recipients (abstract). Interscience Conference on Antimicrobial Agents and Chemotherpay. Washington DC, USA (2004):A25.
72. WEINSTOCK DM, EAGAN J, MALAK SA et al.: Control of influenza A on a bone marrow transplant unit. Infect. Control Hosp. Epidemiol. (2000) 21:730-732.
73. MACHADO CM, BOAS LS, MENDES AV et al.: Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant (2004) 34:111-114.
74. MACHADO CM, BOAS LS, MENDES AV et al.: Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant (2003) 31:695-700.
75. SMALL TN, CASSON A, MALAK SF et al.: Respiratory syncytial virus infection following haematopoietic stem cell transplantation. Bone Marrow Transplant (2002) 29:321-327.
76. HATAKEYAMA N, SUZUKI N, KUDOH T et al.: Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr. Infect. Dis. J. (2003) 22:928-929.
77. LJUNGMAN P: Treatment of adenovirus infections in the immunocompromised host. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:583-588.
78. LJUNGMAN P, RIBAUD P, EYRICH M et al.: Cidofovir for adenovirus infections after allogeneic haematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2003) 31:481-486.
79. Daptomycin (Cubicin) for skin and soft tissue infections. Med. Lett. Drugs Ther. (2004) 46:11-12.
80. Drugs for non-HIV viral infections. Med. Lett. Drugs Ther. (2002) 44:9-16.
81. Antiviral drugs for prophylaxis and treatment of influenza. Med. Lett. Drugs Ther. (2004) 46:85-87.
82. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med. Lett. Drugs Ther. (2000) 42:15-17.
83. Synagis revisited. Med. Lett. Drugs Ther. (2001) 43:13-14.
84. Drugs for non-HIV viral infections. Treat. Guidel. Med. Lett. (2005) 3:23-32.
85. Antifungal drugs. Treat. Guidel. Med. Lett. (2005) 3:7-14.